☰

Roy Maute, Ph.D.

Affiliations: 
2013 Genetics and Development Columbia University, New York, NY 
Area:
Molecular Biology, Biochemistry
Google:
"Roy Maute"
Mean distance: (not calculated yet)
 
Tree Publications Similar researchers PubMed Report error

Parents

Sign in to add mentor
Riccardo Dalla-Favera grad student 2007-2013 Columbia
 (A functional role for transfer RNA-derived microRNAs in human B cells.)
Irving L. Weissman post-doc 2013-2015 Stanford (FlyTree)

Children

Sign in to add trainee
Betty Ha research assistant Ab Initio Biotherapeutics, Inc.
Eddie Irvine research assistant Stanford
Jessie Zhao research assistant 2017- Ab Initio Biotherapeutics, Inc.

Collaborators

Sign in to add collaborator
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Lakhani NJ, Patnaik A, Liao JB, et al. (2020) A phase Ib study of the anti-CD47 antibody magrolimab with the PD-L1 inhibitor avelumab (A) in solid tumor (ST) and ovarian cancer (OC) patients. Journal of Clinical Oncology. 38: 18-18
Fisher GA, Lakhani NJ, Eng C, et al. (2020) A phase Ib/II study of the anti-CD47 antibody magrolimab with cetuximab in solid tumor and colorectal cancer patients. Journal of Clinical Oncology. 38: 114-114
Agoram B, Jin C, Maute R, et al. (2020) Pharmacokinetic (PK)-pharamcodynamic (PD) analysis and receptor occupancy data to support every other week maintenance dosing of magrolimab in combination with azacitidine in MDS/AML patients. Journal of Clinical Oncology. 38: e15098-e15098
Sallman DA, Al Malki M, Asch AS, et al. (2020) Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results. Journal of Clinical Oncology. 38: 7507-7507
Maute RL, Chen JY, Marjon KD, et al. (2019) Translational Study of Cell Surface Proteins in Non-Hodgkin Lymphoma Patients Treated with the First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Rituximab Blood. 134: 5229-5229
Barkal AA, Weiskopf K, Kao KS, et al. (2018) Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nature Immunology. 19: 76-84
Barkal, AA, Weiskopf K, et al. (2017) Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy Nature Immunology
Gordon SR, Maute RL, Dulken BW, et al. (2017) PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature
Mayer AT, Natarajan A, Gordon S, et al. (2016) Practical ImmunoPET radiotracer design considerations for human immune checkpoint imaging. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
Pascolutti R, Sun X, Kao J, et al. (2016) Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant. Structure (London, England : 1993)
See more...